Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1994 1
1995 2
1996 3
1997 2
1998 2
1999 5
2000 3
2001 2
2002 8
2003 5
2004 5
2005 3
2006 2
2007 1
2008 5
2009 6
2010 2
2011 1
2012 1
2013 1
2014 2
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
[Concurrent chemoradiation using daily low-dose CDDP and UFT-E for postoperative recurrent esophageal cancers].
Akagi Y, Hashimoto Y, Takiyama W, Mukaida H, Murakami Y, Ito K. Akagi Y, et al. Gan To Kagaku Ryoho. 2004 Nov;31(12):1993-7. Gan To Kagaku Ryoho. 2004. PMID: 15570927 Review. Japanese.
From October 2001 to January 2004, we treated 6 consecutive patients with radiation and concurrent chemotherapy using daily low-doses of CDDP and UFT-E. Of the 6 patients, 4 (67%) had a complete response and 2 (33%) a partial response, yielding an overall response r …
From October 2001 to January 2004, we treated 6 consecutive patients with radiation and concurrent chemotherapy using daily low-doses of CDD …
Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma.
Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim SY, Yoon HJ, Cho KS, Kim JS. Oh SC, et al. Cancer Res Treat. 2003 Apr;35(2):117-22. doi: 10.4143/crt.2003.35.2.117. Cancer Res Treat. 2003. PMID: 26680924
The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer. ...Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/ …
The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy …
Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Yoon SY, Park KH, Oh SC, Seo JH, Choi CW, Kim BS, Kim JS, Kim CD, Shin SW, Kim YH, Kim JS. Yoon SY, et al. Cancer Res Treat. 2002 Apr;34(2):111-6. doi: 10.4143/crt.2002.34.2.111. Cancer Res Treat. 2002. PMID: 26680851
PURPOSE: To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma. ...Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were di …
PURPOSE: To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment o …
A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer.
Lee WS, Lee KS, Kim KH, Ryoo BY, Kim WS, Kang WK, Kang YK, Heo DS, Bang YJ, Kim NK. Lee WS, et al. Cancer Res Treat. 2001 Jun;33(3):225-8. doi: 10.4143/crt.2001.33.3.225. Cancer Res Treat. 2001. PMID: 26680789
PURPOSE: To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanced colorectal cancer. ...Ten patients had partial responses and one patient complete response (response rate, 31%; 95% confidence interval, …
PURPOSE: To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanc …
[Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area].
Kikuchi K, Wakui A. Kikuchi K, et al. Gan To Kagaku Ryoho. 1990 Nov;17(11):2183-90. Gan To Kagaku Ryoho. 1990. PMID: 2241182 Clinical Trial. Japanese.
Phase II clinical research of UFT E granules (enteric coated) was carried out in 18 institutes (21 clinical dept.) by Study Group of UFT E in Tohoku Area, to investigate its effect and safety on cancer of the digestive organs. ...He recovered from thos …
Phase II clinical research of UFT E granules (enteric coated) was carried out in 18 institutes (21 clinical dept.) by Study Gr …
[Clinical results of UFT granule of enteric coating (UFT E granule). Osaka UFT E Granule Study Group].
Taguchi T. Taguchi T. Gan To Kagaku Ryoho. 1990 Jul;17(7):1295-301. Gan To Kagaku Ryoho. 1990. PMID: 2114825 Clinical Trial. Japanese.
We carried out a Phase II study by single oral administration of UFT granule of enteric coating (UFT E granule) in 40 patients with breast cancer. One CR and 8 PR cases, of which 34 were evaluable, were obtained, and the response rate was 26.5%.; local 28.6%, lymph …
We carried out a Phase II study by single oral administration of UFT granule of enteric coating (UFT E granule) in 40 patients …
[UFT-E granule compliance in postoperative adjuvant chemotherapy].
Komoriyama H, Hanai A, Kanasugi K, Hagiwara M, Yamaguchi S. Komoriyama H, et al. Gan To Kagaku Ryoho. 1999 Aug;26(9):1321-7. Gan To Kagaku Ryoho. 1999. PMID: 10478186 Japanese.
UFT-E granules were administered as postoperative adjuvant chemotherapy to patients who had undergone surgery for gastric cancer, colorectal cancer or breast cancer. ...A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86.3%. Fro …
UFT-E granules were administered as postoperative adjuvant chemotherapy to patients who had undergone surgery for gastric canc …
[A case of hepatocellular carcinoma with autoimmune hepatitis showing marked reduction of tumors by oral administration of UFT-E].
Enomoto H, Ishii A, Imanishi H, Saito M, Tanaka H, Iwata Y, Sakai Y, Iwai T, Yoh K, Takashima T, Yoshikawa S, Aizawa N, Yamamoto T, Ikeda N, Shimomura S, Iijima H, Hirota S, Nishiguchi S. Enomoto H, et al. Gan To Kagaku Ryoho. 2010 May;37(5):919-22. Gan To Kagaku Ryoho. 2010. PMID: 20495329 Japanese.
Since the standard invasive therapies of HCC were not accepted by the patient and his family, he was treated by oral administration of UFT-E (tegafur/uracil: 200 mg/day). Three months after the initiation of administration, CT scan showed a remarkable reduction of t …
Since the standard invasive therapies of HCC were not accepted by the patient and his family, he was treated by oral administration of UF …
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O, Hoshino A, Ohara K, Nagata K, Kojima T, Sugihara T, Yamada M, Suzuki M, Kimura K, Fujii S, et al. Kamiya O, et al. Gan To Kagaku Ryoho. 1983 Dec;10(12):2565-72. Gan To Kagaku Ryoho. 1983. PMID: 6418079 Japanese.
UFT-E, enterogranules of tegafur-uracil (at molar ratio of 1: 4) was developed in order to minimize GI toxicity of UFT. ...In the all doses studied, curves of serum tegafur after administration of UFT-E were consistently higher than those of uracil and …
UFT-E, enterogranules of tegafur-uracil (at molar ratio of 1: 4) was developed in order to minimize GI toxicity of UFT. ...In …
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K. Suenaga M, et al. Surg Today. 2009;39(1):27-31. doi: 10.1007/s00595-008-3843-2. Epub 2009 Jan 8. Surg Today. 2009. PMID: 19132464
The first-line treatments were fluoropyrimidines used alone or in combination with other drugs, such as 5-fluorouracil plus leucovorin (FL), UFT-E, or TS-1. The second-line treatment was irinotecan (CPT-11) monotherapy. ...
The first-line treatments were fluoropyrimidines used alone or in combination with other drugs, such as 5-fluorouracil plus leucovorin (FL), …
66 results